Market: Hong Kong Stock Code: 2137.HK ISIN: KYG1645A1094 Industry: Biotechnology

Brii Biosciences (stock code: 2137.HK) is a biotechnology company developing therapies to address some of the world's most common public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice.



Feb

Aug

Share Data	01/08/2024
Currency HKD	Volume 248,500
Previous Close 1.00	Number of Shares(mil) 729.99
Change (%) -1.96	Share Market Cap (mil) 729.99

Pipeline

Infectious D	isease Programs					
Indication	Program	Preclinical	IND	Phase 1	Phase 2	Phase 3
Hepatitis B Treatment ⁽¹⁾ Prevention	BRII-179					
	BRII-835 (Elebsiran) ⁽²⁾					
	BRII-877 (Tobevibart) (3)					
	PreHevbri ^{TM(4)}					
HIV	BRII-732				•	
	BRII-753					
MDR/XDR Gram- negative Bacterial Infections	BRII-693				•	
NTM Lung Disease	BRII-658 (Epetraborole) ⁽⁵⁾					

Central Nervous System Disease Programs Indication Program Preclinical IND Phase 1 Phase 2 Phase 3 NDA/BLA Commercial Brii Rights **Partners** Internally PPD BRII-296 Global discovered Anxiety & Internally Depressive BRII-297 Global discovered Disorder

- * Greater China Mainland China, Macau, Hong Kong and Taiwan
- (1) The Phase 2 combination clinical trials conducted by Brii:
- BRII-179 / PEG-IFNα
- BRII-179 / BRII-835
- BRII-835 ± PEG-IFNα
- (2) Elebsiran was previously known as VIR-2218.
- (3) Tobevibart was previously known as VIR-3434. The Phase 2 clinical trials have been conducted by VIR.
- (4) VBI launched PreHevbrio/PreHevbri in the United States, Canada, European Union, European Economic Area, the United Kingdom, and Israel. Brii acquired exclusive rights for APAC countries (ex-Japan) in July 2023.
- (5) To this date, the development and clinical trials have been conducted by AN2.

Board of Directors

	Audit and Risk Committee	Nomination Committee	Remuneration Committee	Strategic Committee	Executive Directors	Non-executive Directors	Independent Non-executive Directors
Dr. Zhi Hong		_					
Dr. Ankang Li				<u></u>	<u> </u>		
Dr. Martin J. Murphy Jr.		•					.
Ms. Grace Hui Tang			•				•
Mr. Yiu Wa Alec Tsui	•		•				.
Mr. Gregg Huber Alton		*		•			.
Dr. Taiyin Yang				•			.

Chairperson A Member

CVs of the Board Members



Susannah Cantrell, Ph.D.
Chief Business Officer



Eleanor (Ellee) de Groot, Ph.D.
Chief Technology Officer



Zhi Hong, Ph.D.

Executive Director
Chairman of the Board and
Chief Executive Officer



Brian Alvin Johns, Ph.D.Chief Scientific Officer



Ankang Li, Ph.D., J.D., CFA

Executive Director, Chief
Strategy and Financial Officer
Chief Executive Officer of TSB
Therapeutics



David Margolis, M.D., MPHChief Medical Officer



Karen D. NeuendorffChief People Officer and Head of Human Resources




Qing Zhu, Ph.D.Head of China R&D

CVs of the Corporate Executive Team Members

Financial Highlights			
BRII-B (RMB'000)	2021	2022	2023
Operating Results			
Other income	99,032	107,857	163,728
Other gains and losses	45,062	(12,289)	252,402
Passarch and dayalanment aynoness	(494 615)	(440.634)	(402 705)

Other gains and losses	45,062	(12,289)	252,402
Research and development expenses	(494,615)	(440,634)	(402,705)
Administrative expenses	(208,404)	(168,629)	(196,499)
Fair value loss on financial liabilities at FVTPL	(3,598,847)	-	-
Finance costs	(1,175)	(851)	(494)
Listing expenses	(32,137)	-	-
Loss for the year	(4,191,084)	(489,781)	(184,370)
Financial Position			
Total assets	3,611,699	3,391,849	3,198,251

Total liabilities	300,443	234,352	125,869
Total equity (deficits)	3,311,256	3,157,497	3,072,382
Selected Items from Consolidated Cash Flow Statement			
Net cash used in operating activities	(879,457)	(496,279)	(594,014)
Net cash used in investing activities	(475,756)	(1,433,168)	(104,350)
Net cash from financing activities	3,230,134	(3,042)	(10,977)
Net increase in cash and cash equivalents	1,874,921	(1,932,489)	(709,341)
Cash and cash equivalents at end of the year	2,855,093	1,190,572	489,650
Key indicators			
Loss per share - Basic and diluted (RMB)	(9.48)	(0.67)	(0.24)
Current Ratio	1.22	1.34	2.21



Brii Biosciences Limited

U.S. OFFICES

Durham, NC, United States

WeWork, Suite 05-110, One City Center, 110 Corcoran Street, Durham, NC 27701, United States

San Mateo, CA, United States

WeWork, Suite 02-114, 1825 South Grant Street, San Mateo, CA 94402, United States

Email:ir@briibio.com

CHINA OFFICES

Beijing, China

3rd Floor, Building #7, Zhongguancun, Dongsheng International Science Park, No. 1 North Yongtaizhuang Road, Haidian District, Beijing 100192, P.R.China

Shanghai, China

Room 805, 8th Floor, Kerry Parkside, No.1155 Fangdian Road, Pudong, District, Shanghai 201204, P.R.China



Supplied by © EUROLAND IR®
For terms of use and data vendors information,
see Disclaimer | Cookie policy